Unveiling NLR pathway signatures: EP300 and CPN60 markers integrated with clinical data and machine learning for precision NASH diagnosis.
Journal:
Cytokine
PMID:
39923301
Abstract
BACKGROUND: Given the increasing prevalence of metabolic dysfunction-associated fatty liver disease (MAFLD) and non-alcoholic steatohepatitis (NASH), there is a critical need for accurate non-invasive early diagnostic markers.